2.50
Hdl Handle:
http://hdl.handle.net/10755/161631
Type:
Presentation
Title:
Arginine Supplementation in HIV/Aids
Abstract:
Arginine Supplementation in HIV/Aids
Conference Sponsor:Midwest Nursing Research Society
Conference Year:2002
Author:Swanson, Barbara, DNSc
P.I. Institution Name:Rush University
Title:Assistant Professor
Contact Address:College of Nursing, 600 South Paulina, Suite 1080, Chicago, IL, 60612-3873, USA
Contact Telephone:312.942.8977
Because highly active antiretroviral therapy (HAART) is not consistently associated with restoration of HIV-specific immune responses, there is substantial interest in developing and testing therapies to boost immune responses that will clear HIV-infected cells. We tested the effects of supplemental arginine, a conditionally essential amino acid that has known immunostimulatory properties, on the natural killer (NK) cell activity of persons with HIV/AIDS (N=11). In this double-blind study, participants were randomly assigned to consume 20 grams of arginine/day in capsule form (n=6) or an equivalent number of placebo capsules (n=5) for 14 days. The arginine-supplemented group showed a mean increase in NK cell cytotoxicity of 18.9 lytic units (LU), while the placebo group only showed a 0.3 LU increase. Plasma HIV RNA levels increased by 122 copies/ml in the arginine-supplemented group, while the placebo group showed a decline of 34 copies/ml. The clinical relevance of this increase is uncertain. No adverse effects were associated with arginine supplementation. Although larger trials are warranted, arginine is a promising adjunctive treatment to enhance immune responses in HAART-treated individuals.
Repository Posting Date:
26-Oct-2011
Date of Publication:
17-Oct-2011
Sponsors:
Midwest Nursing Research Society

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleArginine Supplementation in HIV/Aidsen_GB
dc.identifier.urihttp://hdl.handle.net/10755/161631-
dc.description.abstract<table><tr><td colspan="2" class="item-title">Arginine Supplementation in HIV/Aids</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Midwest Nursing Research Society</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2002</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">Swanson, Barbara, DNSc</td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">Rush University</td></tr><tr class="item-author-title"><td class="label">Title:</td><td class="value">Assistant Professor</td></tr><tr class="item-address"><td class="label">Contact Address:</td><td class="value">College of Nursing, 600 South Paulina, Suite 1080, Chicago, IL, 60612-3873, USA</td></tr><tr class="item-phone"><td class="label">Contact Telephone:</td><td class="value">312.942.8977</td></tr><tr class="item-email"><td class="label">Email:</td><td class="value">bswanson@rushu.rush.edu</td></tr><tr><td colspan="2" class="item-abstract">Because highly active antiretroviral therapy (HAART) is not consistently associated with restoration of HIV-specific immune responses, there is substantial interest in developing and testing therapies to boost immune responses that will clear HIV-infected cells. We tested the effects of supplemental arginine, a conditionally essential amino acid that has known immunostimulatory properties, on the natural killer (NK) cell activity of persons with HIV/AIDS (N=11). In this double-blind study, participants were randomly assigned to consume 20 grams of arginine/day in capsule form (n=6) or an equivalent number of placebo capsules (n=5) for 14 days. The arginine-supplemented group showed a mean increase in NK cell cytotoxicity of 18.9 lytic units (LU), while the placebo group only showed a 0.3 LU increase. Plasma HIV RNA levels increased by 122 copies/ml in the arginine-supplemented group, while the placebo group showed a decline of 34 copies/ml. The clinical relevance of this increase is uncertain. No adverse effects were associated with arginine supplementation. Although larger trials are warranted, arginine is a promising adjunctive treatment to enhance immune responses in HAART-treated individuals.</td></tr></table>en_GB
dc.date.available2011-10-26T23:24:35Z-
dc.date.issued2011-10-17en_GB
dc.date.accessioned2011-10-26T23:24:35Z-
dc.description.sponsorshipMidwest Nursing Research Societyen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.